Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An update from Imugene ( (AU:IMU) ) is now available.
Imugene Limited has reported a change in director Paul Hopper’s interests in the company’s securities following the issue of additional performance rights under its Employee Share Option Plan. Hopper, who holds both direct and indirect share interests, received 124,054 new performance rights at no cost, increasing his total performance rights holding to 260,320, in line with shareholder approval granted at the company’s 13 November 2025 annual general meeting. The transaction, which did not involve any disposal of securities or trading during a closed period, reflects ongoing use of equity-based incentives to align director remuneration with shareholder interests.
The most recent analyst rating on (AU:IMU) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Imugene stock, see the AU:IMU Stock Forecast page.
More about Imugene
Imugene Limited is an Australia-listed biotechnology company focused on developing immuno-oncology therapies. The company is engaged in research and clinical development of treatments that harness the immune system to target and treat various cancers, aiming to build a portfolio of innovative cancer immunotherapies for global markets.
Average Trading Volume: 2,053,203
Technical Sentiment Signal: Sell
Current Market Cap: A$99.33M
Find detailed analytics on IMU stock on TipRanks’ Stock Analysis page.